Daria Korolova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daria Korolova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Volodymyr O. Chernyshenko
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv
6 shared publications - Sandor George Vari
International Research and Innovation in Medicine Program, Cedars–Sinai Medical Center, Los Angeles, CA 90048, USA
3 shared publications - Sergiy V. Komisarenko
Department of Molecular Immunology O.V. Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine Kyiv Ukraine
3 shared publications - Tetyana Platonova
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv
3 shared publications - I. V. Us
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
2 shared publications - Svitlana Zhuk
Shupyk National Healthcare University of Ukraine, Kyiv
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Innovative Biosystems and Bioengineering
- Vol. 10 (3) , 11-20
Production and Characterization of Procoagulant Biomaterials Modified With Prothrombin Activator
Background. While several biomaterials used in routine medical settings provide only moderate hemostatic effects, military and disaster medicine require next-generation hemostatic biomaterials with substantially enhanced efficacy to achieve rapid, reliable control of massive hemorrhage. Modification of biomaterials using the enzymatic prothrombin activator (EA) was proposed as a universal approach to improve their procoagulant properties. Objective. The aim of the present work was in vitro and in vivo testing of EA-modified bioactive (carbon sorbent, silicon dioxide), bioinert (cellulose, hydroxyapatite), and biodegradable (collagen, gelatin) biomaterials. Methods. The prothrombin activator was purified using ion-exchange chromatography. A chromogenic substrate assay was used to detect EA washout; modified aggregometry was used to assess the hemostatic properties of modified biomaterials. A rat model of massive liver bleeding was used to evaluate the hemostatic properties of modified biomaterials. Results. EA modification proved feasible across all tested biomaterial classes, with adsorptive immobilization observed. EA-modified biomaterials demonstrated markedly superior hemostatic activity compared to their unmodified forms, significantly shortening bleeding times and reducing blood loss in both in vitro and in vivo settings. Among the matrices evaluated, carbon sorbent and collagen emerged as the most promising carriers: they enabled stable, non-covalent EA binding while fully preserving the enzyme's procoagulant catalytic function, leading to the most pronounced enhancement in hemostatic performance. These findings highlight carbon-sorbent- and collagen-based EA composites as leading candidates for advanced hemostatic agents in high-acuity trauma scenarios. Conclusions. The combination of biomaterials with an enzymatic prothrombin activator creates a new material that preserves the matrix's properties while imparting strong procoagulant activity. Collagen and carbon sorbent were shown to be efficient non-covalent binders of EA and can be used as hemostatic agents in surgery or emergency medicine.
- 4 September 2026
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Innovative Biosystems and Bioengineering
- Vol. 10 (3) , 11-20
Open AccessProduction and Characterization of Procoagulant Biomaterials Modified With Prothrombin Activator
Background. While several biomaterials used in routine medical settings provide only moderate hemostatic effects, military and disaster medicine require next-generation hemostatic biomaterials with substantially enhanced efficacy to achieve rapid, reliable control of massive hemorrhage. Modification of biomaterials using the enzymatic prothrombin activator (EA) was proposed as a universal approach to improve their procoagulant properties. Objective. The aim of the present work was in vitro and in vivo testing of EA-modified bioactive (carbon sorbent, silicon dioxide), bioinert (cellulose, hydroxyapatite), and biodegradable (collagen, gelatin) biomaterials. Methods. The prothrombin activator was purified using ion-exchange chromatography. A chromogenic substrate assay was used to detect EA washout; modified aggregometry was used to assess the hemostatic properties of modified biomaterials. A rat model of massive liver bleeding was used to evaluate the hemostatic properties of modified biomaterials. Results. EA modification proved feasible across all tested biomaterial classes, with adsorptive immobilization observed. EA-modified biomaterials demonstrated markedly superior hemostatic activity compared to their unmodified forms, significantly shortening bleeding times and reducing blood loss in both in vitro and in vivo settings. Among the matrices evaluated, carbon sorbent and collagen emerged as the most promising carriers: they enabled stable, non-covalent EA binding while fully preserving the enzyme's procoagulant catalytic function, leading to the most pronounced enhancement in hemostatic performance. These findings highlight carbon-sorbent- and collagen-based EA composites as leading candidates for advanced hemostatic agents in high-acuity trauma scenarios. Conclusions. The combination of biomaterials with an enzymatic prothrombin activator creates a new material that preserves the matrix's properties while imparting strong procoagulant activity. Collagen and carbon sorbent were shown to be efficient non-covalent binders of EA and can be used as hemostatic agents in surgery or emergency medicine.
- 3 August 2026
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in The Ukrainian Biochemical Journal
- Vol. 98 (4) , 75-85
Markers of prothrombotic state of patients recovered after COVID-19
Background. In recent period the attention of scientists and doctors was focused mainly on methods of COVID-19 treatment. However, clinical course of coronavirus disease strongly affects blood coagulation with the tendency for venous and arterial thrombosis, leading to long-term imbalance between coagulation and anticoagulation systems, which can cause serious danger for health of post-COVID-19 (PCD) patients. Objective. In our work we focused on the analysis of the molecular markers of hemostasis system activation in blood plasma of patients recovered after COVID-19. Methods. Blood plasma samples of 119 seropositive patients recovered from COVID-19 were analysed. The patients were divided into a high-risk group (HRG, n = 163) and a non-risk group (NRG, n = 28) according to WHO recommendations. Patients were examined in a recovery time scale of 1-30; 31-60 days and more than 2 months. Blood plasma samples of seronegative healthy volunteers were collected as the reference group (n = 19). The concentration of soluble fibrin (SF) and D-dimer was measured with sandwich ELISA, generation of activated protein C (PC) and prethrombin-1 (Pre-1)) level with assay using specific chromogenic substrates, and fibrinogen concentration with spectrophotometric method after initiation of coagulation by Ancistron-H. Results. Concentration of fibrinogen, SF and Pre-1 were increased in a blood plasma of patients of NRG and HRG groups in comparison to the reference group. Increasing of fibrinogen and Pre-1 concentrations correlated with COVID-19 stage. The fibrinogen and SF concentrations remained high more than 2 months after recovery in HRG group and elevated after 2 months after recovery in NRG group. D-dimer and protein C levels were elevated in 8% and 11% of PCD patients respectively. Conclusions. Long-term prethrombotic state was more expressed in HRG group of PCD patients. Monitoring of the main coagulation markers can indicate the risk of intravascular thrombus formation in PCD patients. SF, Pre-1 and elevated fibrinogen concentrations were selected as useful thrombosis markers in PCD patients. Keywords: coagulation, COVID-19 patients, D-dimer, fibrinogen, protein C, soluble fibrin, thrombosis
- 3 August 2026
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in The Ukrainian Biochemical Journal
- Vol. 98 (4) , 75-85
Markers of prothrombotic state of patients recovered after COVID-19
Background. In recent period the attention of scientists and doctors was focused mainly on methods of COVID-19 treatment. However, clinical course of coronavirus disease strongly affects blood coagulation with the tendency for venous and arterial thrombosis, leading to long-term imbalance between coagulation and anticoagulation systems, which can cause serious danger for health of post-COVID-19 (PCD) patients. Objective. In our work we focused on the analysis of the molecular markers of hemostasis system activation in blood plasma of patients recovered after COVID-19. Methods. Blood plasma samples of 119 seropositive patients recovered from COVID-19 were analysed. The patients were divided into a high-risk group (HRG, n = 163) and a non-risk group (NRG, n = 28) according to WHO recommendations. Patients were examined in a recovery time scale of 1-30; 31-60 days and more than 2 months. Blood plasma samples of seronegative healthy volunteers were collected as the reference group (n = 19). The concentration of soluble fibrin (SF) and D-dimer was measured with sandwich ELISA, generation of activated protein C (PC) and prethrombin-1 (Pre-1)) level with assay using specific chromogenic substrates, and fibrinogen concentration with spectrophotometric method after initiation of coagulation by Ancistron-H. Results. Concentration of fibrinogen, SF and Pre-1 were increased in a blood plasma of patients of NRG and HRG groups in comparison to the reference group. Increasing of fibrinogen and Pre-1 concentrations correlated with COVID-19 stage. The fibrinogen and SF concentrations remained high more than 2 months after recovery in HRG group and elevated after 2 months after recovery in NRG group. D-dimer and protein C levels were elevated in 8% and 11% of PCD patients respectively. Conclusions. Long-term prethrombotic state was more expressed in HRG group of PCD patients. Monitoring of the main coagulation markers can indicate the risk of intravascular thrombus formation in PCD patients. SF, Pre-1 and elevated fibrinogen concentrations were selected as useful thrombosis markers in PCD patients. Keywords: coagulation, COVID-19 patients, D-dimer, fibrinogen, protein C, soluble fibrin, thrombosis
- Open Access
- 17 December 2025
- Published by PAGEPress Publications in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
- Vol. 98
Interconnection between blood clotting and inflammatory response in patients with acute myocardial infarction
Blood coagulation and inflammation are mutually influenced processes: in the cardiovascular system setting, the inflammatory status following an Acute Myocardial Infarction (AMI) can lead to endothelial dysfunction and activation of the blood coagulation system. This study aimed to evaluate the inflammatory response in AMI and assess its role in predicting prothrombotic state following primary Percutaneous Coronary Interventions (PCI). Fibrinogen concentration was determined spectrophotometrically with a thrombin-like enzyme. D-dimer and Soluble Fibrin (SF) levels were quantified using enzyme-linked immunosorbent assay ELISA. A semi-automatic hematological analyzer was used to evaluate the blood formula. The lipid profile and C-Reactive Protein (CRP) concentration were analyzed using an automatic biochemical analyzer, the Erythrocyte Sedimentation Rate (ESR) was measured using capillary tubes by standard method. Statistical analysis was performed using the Wilcoxon-Mann-Whitney test. The inflammatory marker CRP, White Blood Cell Count (WBC), ESR, and fibrinogen concentration were used to characterize the intensity of inflammation. Patients with elevated CRP levels before PCI exhibited a significantly increased level of SF on the fifth day after AMI, which can be related to a higher risk of thrombosis than patients with AMI and normal inflammatory marker levels. Our findings highlight the importance of inflammation response assessment before the PCI procedures for accurately diagnosing the prothrombotic state of the hemostasis system, predicting thrombosis, and selecting appropriate therapy.
- 17 December 2025
- Published by PAGEPress Publications in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
- Vol. 98
Open AccessInterconnection between blood clotting and inflammatory response in patients with acute myocardial infarction
Blood coagulation and inflammation are mutually influenced processes: in the cardiovascular system setting, the inflammatory status following an Acute Myocardial Infarction (AMI) can lead to endothelial dysfunction and activation of the blood coagulation system. This study aimed to evaluate the inflammatory response in AMI and assess its role in predicting prothrombotic state following primary Percutaneous Coronary Interventions (PCI). Fibrinogen concentration was determined spectrophotometrically with a thrombin-like enzyme. D-dimer and Soluble Fibrin (SF) levels were quantified using enzyme-linked immunosorbent assay ELISA. A semi-automatic hematological analyzer was used to evaluate the blood formula. The lipid profile and C-Reactive Protein (CRP) concentration were analyzed using an automatic biochemical analyzer, the Erythrocyte Sedimentation Rate (ESR) was measured using capillary tubes by standard method. Statistical analysis was performed using the Wilcoxon-Mann-Whitney test. The inflammatory marker CRP, White Blood Cell Count (WBC), ESR, and fibrinogen concentration were used to characterize the intensity of inflammation. Patients with elevated CRP levels before PCI exhibited a significantly increased level of SF on the fifth day after AMI, which can be related to a higher risk of thrombosis than patients with AMI and normal inflammatory marker levels. Our findings highlight the importance of inflammation response assessment before the PCI procedures for accurately diagnosing the prothrombotic state of the hemostasis system, predicting thrombosis, and selecting appropriate therapy.
- Open Access
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9339
Placental Dysfunction Is Associated with Dysregulated Fibrinolytic System Activation
During pregnancy, the maternal hemostatic system undergoes significant changes to support placental angiogenesis, maintain fetal blood flow, and ensure safe delivery. This study investigates the dysregulation of hemostasis in placental insufficiency and explores potential markers for diagnosing and managing this gestational complication. Thromboelastography, coagulation and fibrinolysis functional assays, ELISA, and immunoblotting were employed to assess hemostasis dysregulation in placental dysfunction of two cohorts of pregnant women with placental dysfunction and healthy controls. Thromboelastographic analysis revealed no significant differences in clot lysis indices between the control and placental dysfunction groups, with values remaining within normal ranges, suggesting this method’s limitations for assessing fibrinolysis in pregnancy. The placental dysfunction group demonstrated moderately increased fibrinogen levels and platelet sensitivity to ADP, indicating hemostasis reactiveness. Significantly lower D-dimer levels, decreased plasminogen activator inhibitor activity (total PAI-1 + PAI-2), and increased plasminogen activator activity, driven primarily by uPA in the placental dysfunction group, indicated abnormal fibrinolysis. Immunoblotting confirmed elevated uPA/uPA-PAI complexes and reduced tPA/tPA-PAI complexes, indicating that shutdown of tPA-mediated fibrinolysis and induction of uPA-driven vessel-wall-associated proteolysis are linked to placental dysfunction. Placental dysfunction involves fibrinolytic system dysregulation, marked by decreased PAI and tPA, uPA overproduction, and hypofibrinolysis, contributing to thrombotic risks, impaired placental flow, and complications like fetal growth retardation. PAI/PA ratio and D-dimer levels have diagnostic potential for placental-dysfunction-associated complications.
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9339
Open AccessPlacental Dysfunction Is Associated with Dysregulated Fibrinolytic System Activation
During pregnancy, the maternal hemostatic system undergoes significant changes to support placental angiogenesis, maintain fetal blood flow, and ensure safe delivery. This study investigates the dysregulation of hemostasis in placental insufficiency and explores potential markers for diagnosing and managing this gestational complication. Thromboelastography, coagulation and fibrinolysis functional assays, ELISA, and immunoblotting were employed to assess hemostasis dysregulation in placental dysfunction of two cohorts of pregnant women with placental dysfunction and healthy controls. Thromboelastographic analysis revealed no significant differences in clot lysis indices between the control and placental dysfunction groups, with values remaining within normal ranges, suggesting this method’s limitations for assessing fibrinolysis in pregnancy. The placental dysfunction group demonstrated moderately increased fibrinogen levels and platelet sensitivity to ADP, indicating hemostasis reactiveness. Significantly lower D-dimer levels, decreased plasminogen activator inhibitor activity (total PAI-1 + PAI-2), and increased plasminogen activator activity, driven primarily by uPA in the placental dysfunction group, indicated abnormal fibrinolysis. Immunoblotting confirmed elevated uPA/uPA-PAI complexes and reduced tPA/tPA-PAI complexes, indicating that shutdown of tPA-mediated fibrinolysis and induction of uPA-driven vessel-wall-associated proteolysis are linked to placental dysfunction. Placental dysfunction involves fibrinolytic system dysregulation, marked by decreased PAI and tPA, uPA overproduction, and hypofibrinolysis, contributing to thrombotic risks, impaired placental flow, and complications like fetal growth retardation. PAI/PA ratio and D-dimer levels have diagnostic potential for placental-dysfunction-associated complications.
- Open Access
- 28 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5310
Obesity Is a Thrombotic Risk Factor in Pregnant Women
Background/Objectives: Pregnancy is associated with increased procoagulant conditions, and when combined with obesity, it can elevate the risk of thrombosis. The study aims to assess thrombosis risk markers during pregnancy in relation to obesity. Methods: Somatically healthy women aged 18–42 years with spontaneous pregnancies who did not receive specific antithrombotic treatment were enrolled in the study (n = 97). The participants were divided into groups based on pregestational BMI: the first group consisted of patients who had a BMI ≤ 25 (n = 42), and the second group consisted of patients who were overweight (BMI > 25) and obese (BMI > 30) (n = 55). The control group comprised healthy, non-pregnant, non-obese women (n = 10). Results: Fibrinogen levels, elevated during pregnancy, were higher in the II and III trimesters, with gestational period having a greater influence than BMI. Moderate D-dimer accumulation was observed regardless of obesity, but higher levels were seen in obese women during the III trimester, indicating the dissolution of intravascular fibrin deposits. Soluble fibrin was significantly higher in obese and overweight women during the II trimester and elevated in both groups during the III trimester, correlating with D-dimer accumulation and indicating thrombus formation. A decrease in platelet aggregation ability was observed correlating with D-dimer and soluble fibrin patterns. Conclusions: A significant accumulation of thrombosis risk markers was observed in the III trimester compared to the II, occurring earlier in obese and overweight pregnant women and indicating a higher risk of thrombotic complications in obesity.
- 28 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5310
Open AccessObesity Is a Thrombotic Risk Factor in Pregnant Women
Background/Objectives: Pregnancy is associated with increased procoagulant conditions, and when combined with obesity, it can elevate the risk of thrombosis. The study aims to assess thrombosis risk markers during pregnancy in relation to obesity. Methods: Somatically healthy women aged 18–42 years with spontaneous pregnancies who did not receive specific antithrombotic treatment were enrolled in the study (n = 97). The participants were divided into groups based on pregestational BMI: the first group consisted of patients who had a BMI ≤ 25 (n = 42), and the second group consisted of patients who were overweight (BMI > 25) and obese (BMI > 30) (n = 55). The control group comprised healthy, non-pregnant, non-obese women (n = 10). Results: Fibrinogen levels, elevated during pregnancy, were higher in the II and III trimesters, with gestational period having a greater influence than BMI. Moderate D-dimer accumulation was observed regardless of obesity, but higher levels were seen in obese women during the III trimester, indicating the dissolution of intravascular fibrin deposits. Soluble fibrin was significantly higher in obese and overweight women during the II trimester and elevated in both groups during the III trimester, correlating with D-dimer accumulation and indicating thrombus formation. A decrease in platelet aggregation ability was observed correlating with D-dimer and soluble fibrin patterns. Conclusions: A significant accumulation of thrombosis risk markers was observed in the III trimester compared to the II, occurring earlier in obese and overweight pregnant women and indicating a higher risk of thrombotic complications in obesity.
- Open Access
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6122
Diagnostic Value of Protein C Depletion in Pathologies Associated with the Activation of the Blood Coagulation System
Protein C (PC) is the main anticoagulant protein of the hemostasis system. It can inhibit the blood clotting cascade before the formation of a thrombus, while its concentration can decrease significantly during strong activation of blood clotting. The PC concentration was found to decrease during systemic lupus erythematosus (SLE) (with a median of 75%) and depended heavily on the inflammation index. It was also associated with the accumulation of soluble fibrin monomeric (SFMCs) (with a median of 7 µg/mL). A low PC level was detected during severe ischemic heart disease (IHD) (with medians of 60 and 63%, respectively). These pathologies also were associated with clotting activation. During abdominal aortic aneurysm (AAA), the PC level in blood plasma before surgery was found to range from 40% to 119%. A decrease in the PC level in the blood plasma of patients with AAA before surgery, lower than 78%, was associated with high blood loss (more than 1.5 L). A decrease in the PC level can lead to an imbalance between coagulation and anticoagulation. Thus, during the treatment of complex pathologies associated with the activation of coagulation, specific attention should be paid not only to classic markers of thrombus formation but also to the state of the anticoagulant link.
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6122
Open AccessDiagnostic Value of Protein C Depletion in Pathologies Associated with the Activation of the Blood Coagulation System
Protein C (PC) is the main anticoagulant protein of the hemostasis system. It can inhibit the blood clotting cascade before the formation of a thrombus, while its concentration can decrease significantly during strong activation of blood clotting. The PC concentration was found to decrease during systemic lupus erythematosus (SLE) (with a median of 75%) and depended heavily on the inflammation index. It was also associated with the accumulation of soluble fibrin monomeric (SFMCs) (with a median of 7 µg/mL). A low PC level was detected during severe ischemic heart disease (IHD) (with medians of 60 and 63%, respectively). These pathologies also were associated with clotting activation. During abdominal aortic aneurysm (AAA), the PC level in blood plasma before surgery was found to range from 40% to 119%. A decrease in the PC level in the blood plasma of patients with AAA before surgery, lower than 78%, was associated with high blood loss (more than 1.5 L). A decrease in the PC level can lead to an imbalance between coagulation and anticoagulation. Thus, during the treatment of complex pathologies associated with the activation of coagulation, specific attention should be paid not only to classic markers of thrombus formation but also to the state of the anticoagulant link.
- Open Access
- 9 July 2024
- Published by Springer Nature in Journal of Materials Research
- Vol. 39 (16) , 2332-2347
Argatroban- and copper-modified polymers with improved thromboresistance and antimicrobial properties
This paper describes a novel approach the development of biocompatible polyvinyl chloride (PVC) and polyurethane (PU) polymers, modified with copper (II) ions followed by the immobilisation the thrombin inhibitor argatroban (AG) using dopamine chemistry. The surface loading of the immobilised AG was 6.06 µg cm−2 on PVC and 6.66 µg cm−2 on PU, confirmed by FTIR and inhibitor concentration measurements. Both AG/Cu-modified polymers produced NO by catalytically decomposing S-nitrosothiol, reaching NO levels in plasma of 0.59 × 10–10 $$\text{mol} \, {\text{cm}}^{-2} \, {\text{min}}^{-1}$$ for AG/Cu-PVC and 0.51 × 10–10 $$\text{mol} \, {\text{cm}}^{-2} \, {\text{min}}^{-1}$$ for AG/Cu-PU, matching endothelial cell-produced physiological levels. This modification improved the haemocompatibility of the polymers through thrombin inhibition and reduced platelet aggregation and adhesion. Additionally, both modified polymers inhibited Staphylococcus aureus adhesion, growth and viability, confirming their acquired antibacterial properties. Antibacterial activity against Escherichia coli was also observed. These results demonstrate that modifying PVC and PU surfaces with copper (II) and AG produced materials with dual antithrombotic and antibacterial functions. Graphical abstract- 9 July 2024
- Published by Springer Nature in Journal of Materials Research
- Vol. 39 (16) , 2332-2347
Open AccessArgatroban- and copper-modified polymers with improved thromboresistance and antimicrobial properties
This paper describes a novel approach the development of biocompatible polyvinyl chloride (PVC) and polyurethane (PU) polymers, modified with copper (II) ions followed by the immobilisation the thrombin inhibitor argatroban (AG) using dopamine chemistry. The surface loading of the immobilised AG was 6.06 µg cm−2 on PVC and 6.66 µg cm−2 on PU, confirmed by FTIR and inhibitor concentration measurements. Both AG/Cu-modified polymers produced NO by catalytically decomposing S-nitrosothiol, reaching NO levels in plasma of 0.59 × 10–10 $$\text{mol} \, {\text{cm}}^{-2} \, {\text{min}}^{-1}$$ for AG/Cu-PVC and 0.51 × 10–10 $$\text{mol} \, {\text{cm}}^{-2} \, {\text{min}}^{-1}$$ for AG/Cu-PU, matching endothelial cell-produced physiological levels. This modification improved the haemocompatibility of the polymers through thrombin inhibition and reduced platelet aggregation and adhesion. Additionally, both modified polymers inhibited Staphylococcus aureus adhesion, growth and viability, confirming their acquired antibacterial properties. Antibacterial activity against Escherichia coli was also observed. These results demonstrate that modifying PVC and PU surfaces with copper (II) and AG produced materials with dual antithrombotic and antibacterial functions. Graphical abstract - Open Access
- 27 October 2022
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 6-12
Platelet hemostasis in the implementation of placental dysfunction
Мета дослідження: вивчення стану тромбоцитарної ланки гемостазу у вагітних із плацентарною дисфункцією. Матеріали та методи. Проведено клініко-лабораторний аналіз результатів обстеження 54 пацієнток із плацентарною дисфункцією. До групи контролю увійшли 30 практично здорових жінок із фізіологічним перебігом вагітності. У жінок, включених до дослідження, проводили забір венозної крові для тестування із використанням вакуумних систем у пробірки із 3,8% цитратом натрію. Функціональну активність тромбоцитів вивчали на фотооптичному агрегометрі AP2110 (Солар, Білорусь), тромбоцитограму проводили на гематологічному аналізаторі H18 LIGHT (SFRI SAS, Франція), тромбоеластометричні тести виконані на системі ROTEM delta (Tem Innovations GmbH, Німеччина). Результати. Тромбоцитарний гемостаз має значущий вплив на показник максимальної стійкості до згустків (MCF) за результатами ROTEM у пацієнток із плацентарною дисфункцією. Даний показник може бути ефективним у визначенні гіперреактивності тромбоцитарної ланки у пацієнток із плацентарною дисфункцією. Хоча не виявлено статично значущої різниці між показниками оптичної агрегатометрії індукованої АДФ та колагеном у пацієнток із плацентарною дисфункцією та групою контролю, слід відзначити чітку тенденцію до різкого скорочення lag-періоду колаген-індукованої агрегації тромбоцитів у пацієнток з плацентарною дисфункцією. Висновки. Поряд з пошкодженням ендотелію і коагуляційними змінами порушення у тромбоцитарній ланці гемостазу може відігравати суттєву роль у формуванні тромбофілічного стану у пацієнток із плацентарною дисфункцією. Застосування тесту на основі колаген-індукованої агрегації тромбоцитів може бути перспективним для ефективної діагностики гіперреактивності тромбоцитів. Дослідження тромбоцитарної ланки має стати додатковим елементом лабораторного обстеження з метою вирішення питання щодо необхідності призначення антиагрегантів для профілактики розвитку плацентарної дисфункції.
- 27 October 2022
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 6-12
Open AccessPlatelet hemostasis in the implementation of placental dysfunction
Мета дослідження: вивчення стану тромбоцитарної ланки гемостазу у вагітних із плацентарною дисфункцією. Матеріали та методи. Проведено клініко-лабораторний аналіз результатів обстеження 54 пацієнток із плацентарною дисфункцією. До групи контролю увійшли 30 практично здорових жінок із фізіологічним перебігом вагітності. У жінок, включених до дослідження, проводили забір венозної крові для тестування із використанням вакуумних систем у пробірки із 3,8% цитратом натрію. Функціональну активність тромбоцитів вивчали на фотооптичному агрегометрі AP2110 (Солар, Білорусь), тромбоцитограму проводили на гематологічному аналізаторі H18 LIGHT (SFRI SAS, Франція), тромбоеластометричні тести виконані на системі ROTEM delta (Tem Innovations GmbH, Німеччина). Результати. Тромбоцитарний гемостаз має значущий вплив на показник максимальної стійкості до згустків (MCF) за результатами ROTEM у пацієнток із плацентарною дисфункцією. Даний показник може бути ефективним у визначенні гіперреактивності тромбоцитарної ланки у пацієнток із плацентарною дисфункцією. Хоча не виявлено статично значущої різниці між показниками оптичної агрегатометрії індукованої АДФ та колагеном у пацієнток із плацентарною дисфункцією та групою контролю, слід відзначити чітку тенденцію до різкого скорочення lag-періоду колаген-індукованої агрегації тромбоцитів у пацієнток з плацентарною дисфункцією. Висновки. Поряд з пошкодженням ендотелію і коагуляційними змінами порушення у тромбоцитарній ланці гемостазу може відігравати суттєву роль у формуванні тромбофілічного стану у пацієнток із плацентарною дисфункцією. Застосування тесту на основі колаген-індукованої агрегації тромбоцитів може бути перспективним для ефективної діагностики гіперреактивності тромбоцитів. Дослідження тромбоцитарної ланки має стати додатковим елементом лабораторного обстеження з метою вирішення питання щодо необхідності призначення антиагрегантів для профілактики розвитку плацентарної дисфункції.
- Open Access
- 28 April 2021
- Published by Faculty of Medicine Osijek in Southeastern European medical journal
- Vol. 5 (1) , 47-64
Regulation and Dysregulation of Thrombin Activity
Thrombin is the enzyme of the haemostasis system that stands at the crossroads between the coagulation cascade and coagulation inhibition by protein C, between plasma coagulation factors and cells involved in haemostasis and between haemostasis and the immune system. Allosteric regulation of thrombin and its interaction with various partners in blood plasma and on the surface of the endothelium and platelets provides a wide variety of thrombin functions. The thrombin activity regulation is multifactorial, so a failure of any part of this system leads to serious consequences. An example of this are thrombotic/bleeding complications during endothelial dysfunction, infections, inflammation and uncontrolled treatment.This review aims to summarize current knowledge about thrombin structure, functions and regulation. Collected data suggest a crucial role of thrombin in different pathologies accompanied by blood coagulation disorders, in particular diseases causing endothelial dysfunction, such as COVID-19.
- 28 April 2021
- Published by Faculty of Medicine Osijek in Southeastern European medical journal
- Vol. 5 (1) , 47-64
Open AccessRegulation and Dysregulation of Thrombin Activity
Thrombin is the enzyme of the haemostasis system that stands at the crossroads between the coagulation cascade and coagulation inhibition by protein C, between plasma coagulation factors and cells involved in haemostasis and between haemostasis and the immune system. Allosteric regulation of thrombin and its interaction with various partners in blood plasma and on the surface of the endothelium and platelets provides a wide variety of thrombin functions. The thrombin activity regulation is multifactorial, so a failure of any part of this system leads to serious consequences. An example of this are thrombotic/bleeding complications during endothelial dysfunction, infections, inflammation and uncontrolled treatment.This review aims to summarize current knowledge about thrombin structure, functions and regulation. Collected data suggest a crucial role of thrombin in different pathologies accompanied by blood coagulation disorders, in particular diseases causing endothelial dysfunction, such as COVID-19.